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Receptor signaling: When dimerization is not enough
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Activation of receptors that signal via tyrosine kinase
domains has been thought to involve receptor
dimerization and transphosphorylation of juxtaposed
catalytic domains. Recent results suggest things might
be more complex — specific intersubunit conformational
changes within a dimer can also be important.
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For a wide range of transmembrane receptors, the crucial
event that initiates a signaling pathway inside the cell is
tyrosine phosphorylation. One large class of receptors —
the receptor tyrosine kinases — have an intrinsic tyrosine
kinase domain. Many other receptors, including the large
family of cytokine receptors, lack intrinsic catalytic activ-
ity but associate inside the cell with non-receptor tyrosine
kinases, which act as receptor catalytic subunits. The
accepted model for activation of both types of receptor is
that ligand-induced receptor dimerization juxtaposes the
cytoplasmic tyrosine kinase domains, resulting in
transphosphorylation of regulatory tyrosine residues in the
activation loop of the partner molecule and thereby pro-
moting phosphorylation of target proteins and initiating
signaling cascades. Intrasubunit phosphorylation of the
key regulatory tyrosines is presumably precluded by steric
factors, making oligomerization a requirement for activa-
tion [1]. Recent studies on the erythropoietin (Epo) recep-
tor (EpoR) and the ErbB2/Neu receptor tyrosine kinase,
however, suggest that while dimerization is required, it is
not always sufficient for receptor activation [2–7].
EpoR, a member of cytokine receptor superfamily,
associates constitutively with the non-receptor tyrosine
kinase JAK2 via its cytoplasmic domain. Dogma has it that
unliganded EpoR exists as inactive monomers in
association with JAK2, and that ligand activates EpoR by
inducing dimerization and thereby juxtaposing the JAK2
molecules. Neu/ErbB2, an orphan member of the epider-
mal growth factor (EGF) receptor family, has intrinsic
tyrosine kinase activity. Neu*, an oncogenic form of Neu
with a point mutation in the transmembrane domain —
replacing valine 664 by glutamate — undergoes constitu-
tive dimerization and can induce cell transformation [8].
Glutamate 664 in Neu* is protonated, thus allowing an
interchain hydrogen bond to form between two mutant
transmembrane domains [9]. These observations sug-
gested that dimerization is sufficient for Neu activation.
The EpoR consists of an extracellular domain, referred to
as the Epo-binding protein (EBP), a single transmem-
brane domain and a cytoplasmic domain. The EBP has
two fibronectin type III domains, D1 and D2, connected
via an interdomain region (Figure 1). Despite extensive
evidence for the ligand-induced dimerization model,
Livnah et al. [4] surprisingly found that unliganded EBP
crystallized as a dimer. Interestingly, the unliganded EBP
dimer was seen to adopt a very different conformation
than that of EBP complexed with the peptide agonist
Epo-mimetic peptide 1 (EMP1) [3,4] (Figure 1). In the
unliganded dimer, the two D2 domains are oriented away
from each other at an angle of 135°, and the two trans-
membrane domains are separated by 73 Å. In contrast, in
the EMP1-bound dimer, the D2 domains are oriented
away from each other at an angle of 45° and the transmem-
brane domains are separated by only 39 Å. Moreover,
results from another group had shown that, in the
Epo–(EBP)2 complex, the two D2 domains are aligned
parallel and the transmembrane domains are separated by
a mere 30 Å [10] (Figure 1).
Taken together, these results led Livnah et al. [4] to con-
clude that the cytoplasmic domains of the unliganded
dimers will be kept sufficiently far apart to prevent inter-
action of the two associated JAK2 molecules, thereby
reducing background signaling. Epo or EMP1 binding
would result in receptor reorientation, bringing the trans-
membrane and cytoplasmic domains closer together, thus
facilitating transphosphorylation of the JAK2 molecules.
The results of complementation assays with protein frag-
ments confirmed that unliganded EpoR molecules do
indeed exist as dimers in which the cytoplasmic domains
are kept apart, and that EpoR-associated JAK2 molecules
can physically interact with each other only when EpoR
binds to EMP1 or Epo [5]. These results indicate that at
least a fraction of unliganded EpoR molecules exist as
inactive dimers in vivo. The implication is that dimeriza-
tion by itself is insufficient for EpoR activation, and that
activation of this receptor involves domain reorientation
within a preformed dimer complex.
There is evidence for conformation-dependent activation
of the EpoR dimer in the published literature. For
instance, the antagonist peptide EMP33 inactivates
EpoR but still induces EpoR dimerization. Interestingly,
the relative orientation of the two EBP molecules com-
plexed with EMP33 is different than that of the two EBP
molecules complexed with EMP1 or Epo [2,3,10]. Fur-
thermore, only a small fraction of the bivalent monoclonal
antibodies that bind EBP are activating [11]. It appears,
therefore, that EpoR molecules can form dimers in which
the two subunits have different relative orientations asso-
ciated with ‘on’, ‘off’ or various ‘intermediate’ activity
states. A further indication that the EpoR transmembrane
domain might be designed to dimerize comes from the
observation that substitution of residue arginine 129,
which lies close to the EpoR transmembrane domain, by
cysteine led to dimerization via an intermolecular disul-
fide bond, and that the resulting dimer was constitutively
active [12]. The spacing between the transmembrane
domains in this dimer is presumably less than 30 Å. It will
be important to obtain structural information on the full-
length liganded and unliganded EpoR dimers to deter-
mine the true transmembrane and cytoplasmic domain
spacing in the native protein.
Will what we have learned from these observations about
EpoR turn out to be generally applicable to cytokine
receptor activation? The extracellular domains of cytokine
receptors are highly conserved [13], but no structure has
yet been reported of the unliganded extracellular domain
of a cytokine receptor other than EpoR. One intriguing
indication that the findings with EpoR might be generally
applicable has come from the observation that c-Mpl, a
cytokine receptor for thrombopoietin, was constitutively
activated by the introduction of cysteines into its
membrane-proximal extracellular domain, but not by the
introduction of cysteines nearer its amino terminus [14].
The findings on EpoR activation may have broader
implications for the activation of receptor tyrosine kinases
in general. The transmembrane domains of most growth
factor receptor tyrosine kinases appear to have a conserved
dimerization motif [15], so, in principle at least, they also
could exist as inactive dimers in the absence of ligand.
Furthermore, in the case of the ErbB2/Neu receptor tyro-
sine kinase, it is likely that dimerization is required, but
not necessarily sufficient, for activation. Burke et al. [6]
showed previously that a chimeric form of the Neu recep-
tor containing the transmembrane domain of glyco-
phorin A dimerizes, but does not transform cells and has
only slightly increased kinase activity. The same group [7]
has more recently shown that, when cysteine residues
were introduced at various membrane-proximal positions
of Neu’s extracellular domain, only a subset of the result-
ing receptor dimers had transforming activity. Further-
more, the cysteines in the activating mutants all mapped
to one face of a predicted α helix, the same face as valine
664 which is replaced by glutamate in the oncogenic Neu.
These findings indicate that productive dimerization of
Neu is orientation-dependent — that is, a precise
rotational coupling of the monomers is essential to achieve
activation [7]. The possible existence of inactive receptor
tyrosine kinase dimers is underscored by the finding that
the insulin and insulin-like growth factor 1 (IGF-1)
receptor tyrosine kinases exist as constitutively disulfide-
bonded, inactive (αβ)2 dimers in the unliganded state.
Binding of ligand to these covalent dimers stimulates their
tyrosine kinase activity [16]. In the case of the insulin and
IGF-1 receptors, therefore, ligand binding must induce a
conformational change in preformed dimers that activates
their catalytic domains.
The notion that simple dimerization is insufficient for
receptor activation is also applicable to other types of
receptor of both eukaryotic and prokaryotic origins. One
example is the tumor necrosis factor (TNF) receptor.
TNF binding is thought to result in dimerization or trimer-
ization of free, monomeric receptor molecules, leading to
oligomerization of the cytoplasmic domain and initiation of
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Figure 1
Relative orientations of the extracellular —
‘Epo-binding protein’ (EBP) — region of the
Epo receptor when dimerized in unliganded
(left), EMP1-liganded (middle) or Epo-
liganded (right) states [3,4,10]. The plane of
the membrane is orthogonal to the paper.
Dashed lines project from the carboxyl termini
of the D2 extracellular domains through the
membrane. The liganded complex contains
two EMP1 molecules. Note that the two D2
domains are aligned and separated differently
in the three complexes.
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signaling. Interestingly, however, the extracellular domain
of unliganded TNF receptor-1 was found to exist as a
dimer in two distinct crystal forms [17,18]. In one crystal
form, the two extracellular domains were seen to form an
antiparallel dimer, with the TNF binding site occluded;
the cytoplasmic domains would be predicted to be sepa-
rated in complete dimers by more than 100 Å, preventing
signaling. In the second form, which can in principle bind
TNF, the extracellular domain forms a parallel dimer,
bringing the transmembrane domains close together. TNF
receptor-1 oligomerization has recently been shown to be
actively blocked by binding of the newly identified
protein dubbed ‘silencer of death domains’ (SODD) to its
cytoplasmic domain [19], and this could be a general
mechanism for regulating receptor oligomerization. 
Moving to prokaryotes, the bacterial transmembrane
chemoreceptors, such as the aspartate receptor Tar, provide
a further example. Unliganded Tar is found as a non-cova-
lent dimer. Binding to its chemoattractant ligand does not
change the oligomeric state of Tar, but it does alter the
activity of the associated CheA histidine kinase. This leads,
via a typical ‘two-component’ signal transduction pathway,
to counterclockwise flagellar movement and smooth swim-
ming. The fact that Tar receptors signal without a
monomer–dimer transition once again shows that dimeriza-
tion per se can be insufficient for receptor activation, and
that intersubunit conformational changes and subunit reori-
entation can additionally be involved [20]. 
What are the advantages of the unliganded receptor being
pre-assembled into dimers and there being a strict
requirement for subunit reorientation to activate the
receptor? The presence of unliganded dimers may facili-
tate subsequent formation of ligand–receptor complexes
by increasing the effective receptor concentration. This
may be particularly relevant when a ligand binds to the
first receptor subunit with a high affinity, but to the
second subunit with a much lower affinity, as in the case
of the Epo–EpoR interaction [21]. The insufficiency of
simple dimerization for receptor activation may serve as a
fail-safe mechanism to prevent accidental activation when
two receptor monomers collide during diffusion on the
cell surface. 
There are at least two possible ways that relative domain
orientation can restrict transphosphorylation in a receptor
dimer (Figure 2). Non-activating dimerization may keep
the kinase domains physically apart, as suggested by the
structure of the unliganded EpoR dimer [4,5]. Alterna-
tively, non-activating dimerization may fix the kinase
domains in close proximity but in a wrong or suboptimal
orientation — that is, facing away from each other. This
possibility is suggested by the presence of a non-activating
dimerization interface in Neu [7] and the less-than-
optimal signaling efficiency of different EMPs [2,3,10]. In
both cases, the inactive receptor dimer can be activated by
a rotational coupling process that brings the tyrosine
kinase catalytic domains closer together and/or turns them
around, so that each subunit can present itself as a suitable
substrate for the catalytic domain of the partner molecule.
This, in principle, is similar to the ‘piston-swing’ model
proposed for the regulation of Tar activity [20].
The finding that relative subunit orientation is critically
important for receptor dimer activation presents new
challenges, as well as opportunities, for the design of small
molecule agonists and antagonists. It may prove difficult to
discover small molecules that induce, not only receptor
dimerization, but also the correct conformational reorienta-
tion. Using random phage display peptide libraries and
affinity selection methods, small peptidyl agonists, which
have no sequence homology to the natural ligand Epo but
are capable of inducing dimerization and signaling of
Figure 2
A model for the activation of inactive receptor dimers by rotational
coupling. Top left: an inactive receptor tyrosine kinase dimer, in which
the two catalytic domains are kept apart. Top right: an inactive receptor
tyrosine kinase dimer in which the catalytic domains are in close
proximity but in a wrong or suboptimal orientation (facing away from
each other). Bottom: an active, liganded receptor dimer in which the
two catalytic domains are brought into close proximity in a productive
conformation that allows transphosphorylation and activation. 
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EpoR, have been successfully discovered. In general,
however, these agonists are much less efficient in signaling
than the natural ligand Epo [22,23]. As discussed above,
these Epo-mimetic peptides do not orient the receptor
dimers in the same way as Epo [3,10]. A peptide agonist
that is as potent as the natural cytokine has, however, been
found for the thrombopoietin receptor [24]. 
Very recently, SB 247464, a small dimeric, non-peptidyl
mimic of granulocyte-colony stimulating factor, has been
identified by functional screening [25]. SB 247464 is much
less potent than the natural ligand, perhaps because the
orientation of the two receptor subunits in the dimer is not
optimal for activation. Nevertheless, the fact that subopti-
mal relative subunit orientations can generate dimers with
graded activities may also serve as the basis for the discov-
ery of small compounds that can fine-tune the activity of
target molecules.
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